Astria Therapeutics Enters Material Definitive Agreement
| Field | Detail |
|---|---|
| Company | Astria Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Aug 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, corporate-event
TL;DR
Astria Therapeutics just signed a big deal, filing an 8-K on 8/6/25.
AI Summary
Astria Therapeutics, Inc. announced on August 6, 2025, that it entered into a material definitive agreement. The company, formerly known as Catabasis Pharmaceuticals Inc., is headquartered in Boston, MA, and operates in the pharmaceutical preparations industry.
Why It Matters
This filing indicates a significant new contract or partnership for Astria Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can carry inherent risks related to the terms, counterparty, and execution of the agreement.
Key Players & Entities
- Astria Therapeutics, Inc. (company) — Registrant
- August 6, 2025 (date) — Date of earliest event reported
- Catabasis Pharmaceuticals Inc (company) — Former company name
- Boston, Massachusetts (location) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Astria Therapeutics?
The filing does not specify the details of the material definitive agreement, only that one has been entered into as of August 6, 2025.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on August 6, 2025.
What was Astria Therapeutics' former company name?
Astria Therapeutics, Inc. was formerly known as Catabasis Pharmaceuticals Inc.
Where are Astria Therapeutics' principal executive offices located?
Astria Therapeutics' principal executive offices are located at 22 Boston Wharf Road, 10th Floor, Boston, Massachusetts 02210.
What is the SIC code for Astria Therapeutics?
The Standard Industrial Classification (SIC) code for Astria Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 6, 2025 regarding Astria Therapeutics, Inc..